Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
Information provided by:
National Taiwan University Hospital Identifier:
First received: August 1, 2008
Last updated: August 5, 2008
Last verified: August 2008

A. To investigate the relationship between serum titer of anti-HPV16 antibody and clinicopathological factors of cervical cancer patients.

B. To investigate that if the serum titer of anti-HPV16 antibody could be a prognostic factor in the cervical cancer patients.

C. To investigate the serum titer of anti-HPV16 antibody in HPV16-infected populations with various disease status such as infection only, precancerous lesion, and early and advanced cervical cancer.

Condition Intervention
Cervical Cancer
Cervical Intraepithelial Neoplasia
Procedure: peripheral blood isolation

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and CIN Patients and Their Prognosis

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • overall survival [ Time Frame: from CS operation to close ]

Estimated Enrollment: 600
Study Start Date: December 2005
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: peripheral blood isolation
    To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
  Show Detailed Description


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. cervical intrapeithelial neoplasm
  2. Cervical cancer

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00728871

Contact: Chi-An Chen, MD 886-2-2312-3456 ext 5166

China, Taiwan
Natioanal Taiwan Univ. Hospital Recruiting
Taipei, Taiwan, China, 100
Contact: Chi-An Chen, MD    886-2-2312-3456 ext 5166   
Sponsors and Collaborators
National Taiwan University Hospital
Study Chair: Chi-An Chen, MD National Taiwan University Hospital
Study Chair: Chi-An Chen, MD National Taiwan Univ. Hosp.
  More Information

Responsible Party: Chi-An Chen/Professor, National Taiwan Unviersity Hospital Identifier: NCT00728871     History of Changes
Other Study ID Numbers: 9461700838
Study First Received: August 1, 2008
Last Updated: August 5, 2008

Keywords provided by National Taiwan University Hospital:
cervical cancer, HPV, immunity

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Carcinoma in Situ
Cervical Intraepithelial Neoplasia
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type processed this record on May 22, 2017